Ipamorelin
A selective ghrelin-receptor agonist engineered to stimulate GH release with minimal impact on cortisol or prolactin, compared to older GHRPs.
Research status: Human trials examined GH response and gastric motility; considered the 'cleaner' GHRP in the literature.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
Selected references
- European Journal of Endocrinology · 1998 Ipamorelin, the first selective growth hormone secretagogue
- British Journal of Pharmacology · 1999 Pharmacokinetic and pharmacodynamic study of the growth hormone secretagogue Ipamorelin in humans
- Journal of Gastrointestinal Surgery · 2014 Ipamorelin (a ghrelin agonist) for the treatment of post-operative ileus: a randomized, double-blind, placebo-controlled, phase II study
- Translational Andrology and Urology · 2018 A Review of Growth Hormone Secretagogues
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.
Related in Growth Hormone (GHRP)